ATE400296T1 - Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung - Google Patents

Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung

Info

Publication number
ATE400296T1
ATE400296T1 AT00992589T AT00992589T ATE400296T1 AT E400296 T1 ATE400296 T1 AT E400296T1 AT 00992589 T AT00992589 T AT 00992589T AT 00992589 T AT00992589 T AT 00992589T AT E400296 T1 ATE400296 T1 AT E400296T1
Authority
AT
Austria
Prior art keywords
biological molecules
compositions
methods
lyophilization
stabilizing biological
Prior art date
Application number
AT00992589T
Other languages
English (en)
Inventor
Irina Esikova
Sidney Wolfe
James Thomson
Hora Maninder
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22611688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE400296(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE400296T1 publication Critical patent/ATE400296T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT00992589T 1999-12-02 2000-12-01 Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung ATE400296T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16848699P 1999-12-02 1999-12-02

Publications (1)

Publication Number Publication Date
ATE400296T1 true ATE400296T1 (de) 2008-07-15

Family

ID=22611688

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00992589T ATE400296T1 (de) 1999-12-02 2000-12-01 Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung

Country Status (10)

Country Link
EP (2) EP2292263A3 (de)
JP (2) JP4948731B2 (de)
AT (1) ATE400296T1 (de)
CA (1) CA2393298C (de)
CY (1) CY1108382T1 (de)
DE (1) DE60039450D1 (de)
DK (1) DK1233784T3 (de)
ES (1) ES2307553T3 (de)
PT (1) PT1233784E (de)
WO (1) WO2001041800A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292263A3 (de) 1999-12-02 2011-07-27 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und methoden zur stabilisierung von biologischen Molekülen nach Lyophilisierung
NZ622900A (en) 2001-01-23 2015-11-27 Sanofi Pasteur Inc Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
EP1409013B1 (de) * 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Aluminiumadjuvans und histidin enthaltende impstoffe
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
MXPA05004528A (es) 2002-11-01 2005-07-26 Glaxosmithkline Biolog Sa Composicion inmunogenica.
CN101926988B (zh) 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
EP1651275A1 (de) * 2003-08-05 2006-05-03 Fuji Photo Film B.V. Verwendung von rekombinanten oder synthetischen gelatineartigen proteinen als stabilisator in lyophilisierten pharmazeutischen zusammensetzungen
JP2007509164A (ja) 2003-10-23 2007-04-12 カイロン コーポレイション 安定化組成物
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
AR056396A1 (es) 2005-06-27 2007-10-10 Glaxosmithkline Biolog Sa Composicion inmunogenica
ATE554788T1 (de) 2006-03-22 2012-05-15 Novartis Ag Schemata zur immunisierung mit meningokokken- konjugaten
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
TW201009337A (en) * 2008-05-30 2010-03-01 Intervet Int Bv Analytical method to monitor vaccine potency and stability
KR20110079693A (ko) 2008-10-29 2011-07-07 와이어쓰 엘엘씨 단일 도메인 항원 결합 분자의 정제 방법
BR122018013284B1 (pt) * 2008-10-29 2022-03-03 Ablynx N.V Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab
BR112012030950B1 (pt) 2010-06-04 2020-02-04 Wyeth Llc composição imunogênica multivalente, formulação, frasco, dispositivo de distribuição de vacinas pré-enchido, kit, e recipiente
EP3246044B2 (de) 2010-08-23 2024-04-10 Wyeth LLC Stabile formulierungen von neisseria-meningitidis-rlp2086-antigenen
ES2864635T3 (es) 2010-09-10 2021-10-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
AU2012222883A1 (en) 2011-03-02 2013-10-17 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
WO2012163289A1 (zh) 2011-06-01 2012-12-06 厦门大学 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
EP2793939A1 (de) * 2011-12-23 2014-10-29 Novartis AG Stabile zusammensetzungen zur immunisierung gegen staphylococcus aureus
IN2012MU00206A (de) 2012-01-20 2013-08-09
EP2822584A1 (de) 2012-03-08 2015-01-14 Novartis AG Kombinationsimpfstoffe mit tlr4-agonisten
WO2013132452A2 (en) 2012-03-09 2013-09-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
NZ703260A (en) * 2012-05-30 2017-07-28 The Brigham And Women’S Hospital Inc Polysaccharide compositions and methods of use
EP2866792A4 (de) * 2012-06-28 2016-08-17 Ansun Biopharma Inc Mikropartikelformulierungen zur abgabe an die unteren und zentralen atemwege und verfahren zur herstellung
WO2014009971A2 (en) * 2012-07-07 2014-01-16 Bharat Biotech International Limited Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
RU2015106930A (ru) 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
CA2896552A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic compositions
CN105007935A (zh) 2012-12-18 2015-10-28 葛兰素史密丝克莱恩生物有限公司 用于保护免于白喉和/或破伤风的缀合物
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
KR20210002757A (ko) 2013-09-08 2021-01-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
AU2019376832B2 (en) 2018-11-06 2024-01-25 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
BR112022004921A2 (pt) 2019-09-27 2022-07-19 Pfizer Composições para neisseria meningitidis e métodos das mesmas
GB202208089D0 (en) * 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
EP2275119B1 (de) * 1995-07-27 2013-09-25 Genentech, Inc. Stabile isotonische lyophilisierte Proteinzusammensetzung
EP2292263A3 (de) 1999-12-02 2011-07-27 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und methoden zur stabilisierung von biologischen Molekülen nach Lyophilisierung

Also Published As

Publication number Publication date
CA2393298A1 (en) 2001-06-14
EP2292263A2 (de) 2011-03-09
WO2001041800A3 (en) 2002-01-03
ES2307553T3 (es) 2008-12-01
EP2292263A3 (de) 2011-07-27
EP1233784A2 (de) 2002-08-28
CA2393298C (en) 2011-02-01
PT1233784E (pt) 2008-11-03
JP2003516361A (ja) 2003-05-13
JP4948731B2 (ja) 2012-06-06
JP2011137047A (ja) 2011-07-14
DE60039450D1 (de) 2008-08-21
WO2001041800A9 (en) 2002-08-01
CY1108382T1 (el) 2014-02-12
DK1233784T3 (da) 2008-09-01
EP1233784B1 (de) 2008-07-09
WO2001041800A2 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
ATE400296T1 (de) Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
DE69433530D1 (de) Bmp-11 zusammensetzungen
DK0535091T3 (da) Knogleinducerende farmaceutiske formuleringer
DK0429570T3 (da) Osteoinducerende præparater
DK1041072T3 (da) Dioxocyclopentylhydroxamsyrer
NO20025450D0 (no) Ny farmasöytisk sammensetning
ATE223486T1 (de) Bmp-9 zusammensetzungen
ATE265529T1 (de) Bmp-10 zusammensetzungen
BR0210282A (pt) Veìculos de distribuição de fosfato de cálcio para proteìnas osteoindutivas
ATE218579T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen
ATE444086T1 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln
DE69821793D1 (de) Neuronale verwendungen des bmp-11
ATE321045T1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
DE60020729D1 (de) Verfahren und zusammensetzung zur behandlung von adenovirale augeninfektionen
DE60011601D1 (de) Rekombinantes sp-a zur behandlung und vorbeugung von pulmonaren infektionen und entzündungen
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
KR950700896A (ko) 신규의 심장 보호제(Novel Cardioprotective Agents)
DE60028682D1 (de) Wachstumhormone Inhibitoren Enthaltende pharmazeutische Zubereitungen oder ihre biologisch aktive Fragmente zur Behandlung von uterinen Myomas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1233784

Country of ref document: EP